NURPF Stock UPDATES Neuren Pharmaceutica (NURPF) 0.0897 09/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neuren Pharmaceutica (NURPF) 0.0897 $NURPF

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5b6wvm/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Neuren Pharmaceuticals Limited - Paladin Labs Inc. - Protemix Corporation Limited - Relevare Pharmaceuticals Ltd. - Regenesance BV For more information visit http://www.researchandmarkets.com/research/5b6wvm/peripheral

Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products




Scroll down for more posts ▼

Top 10 Most Recent News Articles

RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 138

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 16

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Miami Office Puts Dubai Closer to U.S. Business Deal Flow

Updated Category News Views 68

Miami is not a random pin on a map; it is a deliberate front door to the Americas, and Dubai International Chamber has decided it needs someone standing in it. The chamber opened a representative office there on November 19, 2026, its second in the United States after launching in New York during the Dubai Business Forum – USA in November 2025. This is not the sort of...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 144

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 53

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 102

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Unveils New Wealth Management Tools for Advisors

Updated Category News Views 212

Orion Unveils New Wealth Management Tools for Advisors Orion, known for empowering financial advisors with cutting-edge wealth management solutions, is excited to announce a series of significant enhancements aimed at assisting advisors in servicing high-net-worth (HNW) and ultra-high-net-worth (UHNW) clientele. As new economic paradigms shift with generational wealth...

Continue Reading
Myriad Genetics Enhances Breast Cancer Research with Collaborations

Updated Category News Views 119

Myriad Genetics Expands Research Collaborations for Breast Cancer Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s...

Continue Reading
Man Group PLC Discloses Significant Position in American Axle

Updated Category News Views 158

Significant Position Disclosure by Man Group PLC Man Group PLC, a global investment management firm, has made a notable disclosure concerning its significant interests in American Axle & Manufacturing Holdings, Inc. This disclosure falls under Rule 8.3 of the UK Takeover Code, which mandates disclosure by entities holding 1% or more of relevant securities in any company...

Continue Reading
Legal Protection Steps for Jasper Therapeutics Investors

Updated Category News Views 223

Understanding the Importance of Legal Counsel Deciding to invest in a company like Jasper Therapeutics, Inc. (NASDAQ: JSPR) can be a significant move, but it's crucial to be aware of the potential challenges that come with investing in securities. Individuals who have bought shares in Jasper Therapeutics between certain dates should pay close attention to upcoming...

Continue Reading
TotalEnergies Expands on Gas Strategy with Latest Acquisition

Updated Category News Views 124

TotalEnergies Expands on Gas Strategy with Latest Acquisition TotalEnergies SE (TTE) shares have shown an upward trend, particularly in premarket trading. Recently, the company announced a notable agreement with Lewis Energy Group that involves acquiring a significant 45% stake in its dry gas-producing assets located in the Eagle Ford Basin, Texas. Details of the...

Continue Reading